Outcomes of immune tolerance induction with rituximab to eradicate high-titer inhibitor of hemophilia A: depicted by exponential decay model and the gene expression profile of different outcomes by RNA-sequencing

This publication has 56 references indexed in Scilit:

• CD38: An important regulator of T cell function
  Biomedicine & Pharmacotherapy, 2022
• Low‐dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors
  Research and Practice in Thrombosis and Haemostasis, 2021
• Haemophilia
  Nature Reviews Disease Primers, 2021
• Chitinase-3 like-protein-1 function and its role in diseases
  Signal Transduction and Targeted Therapy, 2020
• Current view and outcome of ITI therapy - A change over time?
  Thrombosis Research, 2016
• Impact of inhibitors on hemophilia a mortality in the United States
  American Journal of Hematology, 2015
• Carbohydrate-binding motif in chitinase 3-like 1 (CHI3L1/YKL-40) specifically activates Akt signaling pathway in colonic epithelial cells
  Clinical Immunology, 2011
• Inhibitor treatment by rituximabin congenital haemophilia A
  Hamostaseologie, 2009
• Successful suppression using Rituximab of a factor VIII inhibitor in a boy with severe congenital haemophilia: An example of a significant decrease of treatment costs
  Thrombosis and Haemostasis, 2006
• The North American Immune Tolerance Registry: Practices, Outcomes, Outcome Predictors
  Thrombosis and Haemostasis, 2002